Although former President Trump offered state Medicaid programs discounted prices on weight-loss medications, most have chosen not to participate. This move underscores the complexities of negotiating drug costs for a wide and diverse patient base.

Pfizer made headlines by forging a drug pricing agreement with the Trump administration, surprising many in the pharmaceutical industry. The move exposed rifts within Big Pharma, as other companies were left scrambling to respond.